Verve Therapeutics
Joe is vice president, editing development at Verve Therapeutics. Working for nearly a decade in the biotechnology industry, Joe brings broad experience in early and late-stage drug development, basic and clinical research, medical affairs, alliance management, and program leadership. Prior to joining Verve, he was vice president, program, and portfolio management at Shape Therapeutics. Joe began his career in medical affairs at Dyax, followed by a number of roles in both medical affairs and program leadership at Bluebird Bio. He received his B.A. in philosophy from the University of Vermont, a PhD in neuroscience from the University of Colorado at Boulder and completed his post-doctoral studies at the Picower Institute for Learning and Memory at MIT and the US Army Research Institute for Environmental Medicine.
This person is not in any offices
Verve Therapeutics
59 followers
Verve Therapeutics is a biotechnology company focused on discovering and developing therapies that safely edit the genomes of adults to confer lifelong protection against coronary artery disease, the most common type of heart disease and the leading cause of death worldwide.